Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns

Key Points

• Dow is strategically positioned in materials science, with initiatives that demonstrate a commitment to long-term sustainability and innovation.
• Verizon's commitment to expanding its 5G network, combined with its growing FWA subscriber base, makes it attractive for income-focused investors.
• Pfizer's pharmaceutical product pipeline and recent strategic acquisitions are expected to drive growth and support its robust dividend yield.

 

For most investors, generating consistent income alongside capital appreciation is a common goal. For those seeking a blend of stability and yield, high-yield blue-chip stocks often present a compelling proposition. These stocks represent financially healthy companies that offer a history of reliable dividend payments, making them attractive to investors.

"Blue chip" is a term that signifies a large, reputable company with a long history of financial performance. These are typically industry leaders with substantial market capitalization, consistent revenue and earnings, and often, a dominant market share. Their established presence and financial stability make them less volatile than smaller, growth-oriented companies. 

High-yield stocks are those that pay dividends significantly above the market average. A higher dividend yield suggests a larger portion of the stock's value is returned to shareholders as dividends. The allure of high-yield blue chips lies in their potential to provide a steady income stream, lower volatility, and the prospect of long-term capital appreciation. These attributes make them appealing in times of economic uncertainty or low interest rates, offering a potential haven for investors seeking income and relative stability. 

Dow: A Materials Science Titan

Dow Inc. NYSE: DOW is a global leader in materials science. The company offers a diverse portfolio of chemicals, plastics, and agricultural products. Dow’s dividend yield is currently set at an impressive 7.22%. Dow’s yield is influenced by several factors, including the inherent cyclicality of the chemical industry and recent market concerns about a potential global economic slowdown, which have put downward pressure on Dow's stock price, creating a compelling entry point for investors. 

Dow's long-term prospects remain bright. The company is strategically positioned to capitalize on the increasing global demand for its products, particularly in high-growth sectors like packaging, infrastructure, and agriculture. Dow's commitment to innovation and sustainability is also expected to be a significant growth driver. For the third quarter of 2024, Dow reported net sales of $10.9 billion and an operating EBIT of $641 million. These figures reflect the company's ability to navigate a complex market environment while generating substantial revenue.

The company is actively pursuing initiatives to enhance its long-term value. The Path2Zero project, a significant undertaking aimed at reducing carbon emissions, is making headway with major foundational work underway. Additionally, Dow's "Transform the Waste" strategy, which targets over $500 million in EBITDA by 2030 through waste reduction and recycling efforts, underscores its commitment to sustainability and operational efficiency. Dow is also making strides in recycling and materials science.

Notably, a partnership with Delian Group aims to expand the use of post-consumer recycled resins in the automotive market, and a collaboration with Ambipar in Brazil targets a significant increase in polyethylene recycling. These initiatives, along with Dow's continued presence on the Dow Jones Sustainability World Index for 24 consecutive years, highlight its dedication to environmental responsibility.

Verizon: A Telecommunications Behemoth

Verizon Communications Inc. NYSE: VZ is one of the top companies in the U.S. telecommunications sector. Verizon offers a comprehensive range of wireless and wireline services. The company's current dividend yield of 7.00% makes it a compelling option for income-focused investors. In the third quarter of 2024, Verizon reported revenue of $33.3 billion, with wireless service revenue growing 2.7% year-over-year to $19.8 billion. The company also achieved an adjusted EBITDA of $12.5 billion, demonstrating its ability to generate substantial earnings. Verizon added 389,000 total broadband net additions in the same quarter, highlighting continued demand for its services.

Verizon is making significant strides in expanding its 5G network, a move expected to unlock new revenue streams and enhance its competitive position. Its fixed wireless access (FWA) service continues to gain traction, with nearly 4.2 million subscribers as of the end of Q3 2024. Verizon has also set an ambitious target of reaching 8-9 million FWA subscribers by 2028.

Moreover, Verizon is strategically expanding its fiber network, aiming for 35-40 million passings over time. This includes the pending acquisition of Frontier Communications, which is expected to add approximately 9-10 million fiber passings. To further enhance its capabilities, Verizon has engaged in a tower transaction with Vertical Bridge, acquired spectrum from U.S. Cellular, and formed a new satellite partnership with Skylo.

Pfizer: A Pharmaceutical Powerhouse

Pfizer Inc. NYSE: PFE has a diverse portfolio of drugs and vaccines supported by a healthy research and development pipeline. Despite a recent decline in revenue, primarily attributed to lower COVID-19 vaccine sales, Pfizer maintains a solid financial position and offers a dividend yield of 6.43%. 

For the third quarter of 2024, Pfizer reported revenues of $17.7 billion, marking a 32% operational growth and a reported net income of $4.465 billion. The company continues to see growth in its oncology products, including Padcev, Xtandi, Lorbrena, and Braftovi/Mektovi.

Additionally, Pfizer has provided a full-year 2025 revenue guidance of $61.0 to $64.0 billion and an adjusted diluted EPS guidance range of $2.80 to $3.00.

Pfizer's future growth is expected to be driven by its strong product pipeline, which includes several potential blockbuster drugs in different stages of development.

The company's ongoing R&D efforts, combined with strategic acquisitions and partnerships, are designed to bolster its product portfolio and ensure long-term growth.

The recent FDA approval of BRAFTOVI, combined with other treatments for metastatic colorectal cancer with a BRAF V600E mutation, highlights Pfizer's innovative capabilities and ability to bring new, effective therapies to market.

Investing in the Future

Investing in high-yield blue-chip stocks like Dow Inc., Verizon, and Pfizer can be a prudent strategy for investors seeking a blend of income and potential capital appreciation. With their established market positions, strong financial performances, and attractive dividend yields, these companies offer a compelling proposition for those looking to enhance their investment portfolios.